November 3, 2005Journal of Hypertension
Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds
Key result
Angiotensin receptor blockers (ARBs) showed no evidence of increased risk of fatal and non-fatal myocardial infarction compared with placebo or active treatments.
Why the study?
Do angiotensin receptor blockers (ARBs) increase the risk of fatal and non-fatal myocardial infarction compared to placebo or active treatment?
Population
Patients in major international, randomized trials evaluating angiotensin receptor blockers
Comparison
Angiotensin receptor blockers (ARBs) vs Placebo or active treatment
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
ARBs do not increase MI risk; challenges prior concerns and reinforces safe use in hypertension.
Study Design
Type
Meta-Analysis
Structured PICO
Do angiotensin receptor blockers (ARBs) increase the risk of fatal and non-fatal myocardial infarction compared to placebo or active treatment?
P
Population
Patients in major international, randomized trials evaluating angiotensin receptor blockers
I
Intervention
Angiotensin receptor blockers (ARBs)
C
Comparator
Placebo or active treatment (including angiotensin-converting enzyme inhibitors)
O
Outcome
Fatal and non-fatal myocardial infarctionhard clinical
This meta-analysis refutes previous concerns by demonstrating that ARBs do not increase the risk of myocardial infarction compared to placebo or active treatments like ACE inhibitors.
Cite This Study
Volpe et al. (2005) conducted a meta-analysis in Myocardial infarction. Angiotensin receptor blockers (ARBs) vs. Placebo or active treatment (including ACEIs) was evaluated on Fatal and non-fatal myocardial infarction. Angiotensin receptor blockers (ARBs) showed no evidence of increased risk of fatal and non-fatal myocardial infarction compared with placebo or active treatments.